Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK-R215
- Development stage
- Phase 1
- Lead developer
- Alvogen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**AK-R215** is an Alvogen Korea fixed-dose oral combination of the selective estrogen receptor modulator bazedoxifene and cholecalciferol. The registered Phase 1 pharmacokinetic study evaluated AK-R215 against loose coadministration of bazedoxifene 20 mg and cholecalciferol 800 IU in healthy adult men and menopausal women. Bazedoxifene provides tissue-selective estrogen-receptor modulation relevant to bone preservation, while cholecalciferol is metabolically activated to vitamin D metabolites that activate the vitamin D receptor and support calcium and phosphate homeostasis. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03321318?viewType=Table))
- Other names
- bazedoxifene + cholecalciferol
02
Targets
ESR1 (ERα)ESR2 (ERβ)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on AK-R215.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK-R215.